Código QR (código de barras bidimensional)

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer

BackgroundTucatinib is an oral human epidermal growth factor receptor 2 (HER2)-directed therapy approved in combination with trastuzumab and capecitabine for use in patients with previously treated HER2+ metastatic breast cancer (MBC) with/without brain metastases (BM). To inform clinical decision-m...

ver descrição completa

Na minha lista:
Principais autores: Peter A. Kaufman, Edward Neuberger, Naomi R. M. Schwartz, Shu Wang, Yutong Liu, Ling-I Hsu, Karen Bartley, Matthew T. Blahna, Brian T. Pittner, Gabriel Wong, Carey Anders
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2023-10-01
coleção:Frontiers in Oncology
Assuntos:
metastatic breast cancer
HER2+
brain metastases
tucatinib
real-world
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2023.1264861/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados